Abstract
Diabetes mellitus in companion animals represents a complex endocrine disorder with increasing prevalence, particularly in dogs and cats, requiring individualized and species-specific therapeutic approaches. This systematic review was conducted in accordance with the PRISMA 2020 Statement and compares two major therapeutic strategies—insulin therapy and sodium–glucose cotransporter 2 (SGLT2) inhibitors—while also analyzing factors influencing treatment selection, safety profiles, and emerging therapeutic perspectives. Insulin remains the cornerstone of diabetes management in both dogs and cats, providing reliable glycemic control across all disease stages, although its use is limited by the risk of hypoglycemia and the need for injectable administration and continuous monitoring. In contrast, SGLT2 inhibitors offer a novel oral, insulin-independent approach that improves owner compliance and demonstrates promising efficacy in selected stable feline patients, but their use is restricted by the risk of euglycemic ketoacidosis and limited applicability in insulin-dependent diabetes. Therapeutic decision-making is influenced by multiple factors, including species differences, disease pathophysiology, comorbidities, hepatic function, clinical experience, and owner-related constraints. Emerging therapies such as stem cell therapy, gene therapy, GLP-1 analogs, and advanced insulin delivery systems highlight the evolving landscape of veterinary diabetology and the potential for more personalized and regenerative treatment strategies in the future.

This publication has 43 references indexed in Scilit: